公开(公告)号：CZ90999A3

公开(公告)日：1999-06-16

申请号：CZ90999

申请日：1997-09-15

Applicant: HOECHST AG

Inventor： ERTL JOHANN ,  PREIBISCH GERALD ,  MULLER GUNTER

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K45/00 ,  A61P3/10 ,  A61P5/50 ,  C07K14/575 ,  C07K16/26 ,  C07K19/00 ,  C12P21/02

Abstract: The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.

公开(公告)号：AU4458697A

公开(公告)日：1998-04-14

申请号：AU4458697

申请日：1997-09-15

Applicant: HOECHST AG

Inventor： MUELLER GUENTER ,  PREIBISCH GERALD ,  ERTL JOHANN

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K45/00 ,  A61P3/10 ,  A61P5/50 ,  C07K14/575 ,  C07K16/26 ,  C07K19/00 ,  C12P21/02

Abstract: The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.

公开(公告)号：FI881268A

公开(公告)日：1988-09-21

申请号：FI881268

申请日：1988-03-17

Applicant: HOECHST AG

Inventor： RAGG HERMANN ,  PREIBISCH GERALD ,  HEIN FRIEDRICH ,  UHLMANN EUGEN ,  LINDENMAIER WERNER

IPC: G01N33/50 ,  A61K38/00 ,  A61K38/55 ,  C07K14/00 ,  C07K14/435 ,  C07K14/575 ,  C07K14/81 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/68 ,  C12Q1/6876 ,  C12R1/91 ,  C12N

Abstract: Human leuserpine-2 (hLS2) has the same gene structure as alpha -antitrypsin or angiotensinogen. By combination of exons from serpine genes which have this gene structure, recombinant genes can be produced which code for hybrid serpines. By expression of the recombinant genes in eukaryotic cells, the corresponding hybrid serpines can be obtained.

公开(公告)号：ZA9708455B

公开(公告)日：1998-03-20

申请号：ZA9708455

申请日：1997-09-19

Applicant: HOECHST AG

Inventor： MUELLER GUENTER ,  PREIBISCH GERALD ,  ERTL JOHANN

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K45/00 ,  A61P3/10 ,  A61P5/50 ,  C07K14/575 ,  C07K16/26 ,  C07K19/00 ,  C12P21/02 ,  A61K

CPC classification number: C07K14/5759 ,  A61K38/00

公开(公告)号：AU1328888A

公开(公告)日：1988-09-22

申请号：AU1328888

申请日：1988-03-18

Applicant: HOECHST AG

Inventor： RAGG HERMANN ,  PREIBISCH GERALD ,  HEIN FRIEDRICH ,  UHLMANN EUGEN ,  LINDENMAIER WERNER

IPC: G01N33/50 ,  A61K38/00 ,  A61K38/55 ,  C07K14/00 ,  C07K14/435 ,  C07K14/575 ,  C07K14/81 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/68 ,  C12Q1/6876 ,  C12R1/91 ,  C07G17/00 ,  C07H21/04 ,  C07K3/28 ,  C07K13/00 ,  C12N5/00 ,  C12N9/64 ,  C12N15/00 ,  G01N33/53

Abstract: Human leuserpine-2 (hLS2) has the same gene structure as alpha -antitrypsin or angiotensinogen. By combination of exons from serpine genes which have this gene structure, recombinant genes can be produced which code for hybrid serpines. By expression of the recombinant genes in eukaryotic cells, the corresponding hybrid serpines can be obtained.

公开(公告)号：FI881268A0

公开(公告)日：1988-03-17

申请号：FI881268

申请日：1988-03-17

Applicant: HOECHST AG

Inventor： RAGG HERMANN ,  PREIBISCH GERALD ,  HEIN FRIEDRICH ,  UHLMANN EUGEN ,  LINDENMAIER WERNER

IPC: G01N33/50 ,  A61K38/00 ,  A61K38/55 ,  C07K14/00 ,  C07K14/435 ,  C07K14/575 ,  C07K14/81 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/68 ,  C12Q1/6876 ,  C12R1/91 ,  C12N

Abstract: Human leuserpine-2 (hLS2) has the same gene structure as alpha -antitrypsin or angiotensinogen. By combination of exons from serpine genes which have this gene structure, recombinant genes can be produced which code for hybrid serpines. By expression of the recombinant genes in eukaryotic cells, the corresponding hybrid serpines can be obtained.

公开(公告)号：ZA978455B

公开(公告)日：1998-03-20

申请号：ZA978455

申请日：1997-09-19

Applicant: HOECHST AG

Inventor： MUELLER GUENTER ,  PREIBISCH GERALD ,  ERTL JOHANN

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K45/00 ,  A61P3/10 ,  A61P5/50 ,  C07K14/575 ,  C07K16/26 ,  C07K19/00 ,  C12P21/02 ,  A61K

Abstract: The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.

公开(公告)号：DK151788D0

公开(公告)日：1988-03-18

申请号：DK151788

申请日：1988-03-18

Applicant: HOECHST AG

Inventor： RAGG HERMANN ,  PREIBISCH GERALD ,  HEIN FRIEDRICH ,  UHLMANN EUGEN ,  LINDENMAIER WERNER

IPC: G01N33/50 ,  A61K38/00 ,  A61K38/55 ,  C07K14/00 ,  C07K14/435 ,  C07K14/575 ,  C07K14/81 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/68 ,  C12Q1/6876 ,  C12R1/91 ,  C07K15/04 ,  C07H21/04 ,  C12N5/00 ,  C12N15/00 ,  C12P19/34

Abstract: Human leuserpine-2 (hLS2) has the same gene structure as alpha -antitrypsin or angiotensinogen. By combination of exons from serpine genes which have this gene structure, recombinant genes can be produced which code for hybrid serpines. By expression of the recombinant genes in eukaryotic cells, the corresponding hybrid serpines can be obtained.

公开(公告)号：AU735178B2

公开(公告)日：2001-07-05

申请号：AU4458697

申请日：1997-09-15

Applicant: HOECHST AG

Inventor： MUELLER GUENTER ,  PREIBISCH GERALD ,  ERTL JOHANN

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K45/00 ,  A61P3/10 ,  A61P5/50 ,  C07K14/575 ,  C07K16/26 ,  C07K19/00 ,  C12P21/02

Abstract: The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.

公开(公告)号：PL332458A1

公开(公告)日：1999-09-13

申请号：PL33245897

申请日：1997-09-15

Applicant: HOECHST AG

Inventor： ERTL JOHANN ,  PREIBISCH GERALD ,  MUELLER GUENTER

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K45/00 ,  A61P3/10 ,  A61P5/50 ,  C07K14/575 ,  C07K16/26 ,  C07K19/00 ,  C12P21/02

Abstract: The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.